Ihab Eldessouki

524 total citations
23 papers, 337 citations indexed

About

Ihab Eldessouki is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Ihab Eldessouki has authored 23 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Surgery. Recurrent topics in Ihab Eldessouki's work include Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Lung Cancer Research Studies (5 papers). Ihab Eldessouki is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Lung Cancer Research Studies (5 papers). Ihab Eldessouki collaborates with scholars based in United States, Egypt and Italy. Ihab Eldessouki's co-authors include Mohamed Rahouma, Nagla Abdel Karim, John C. Morris, Mohamed Kamel, Nagla Abdel Karim, Adham Elmously, Massimo Baudo, Changchun Xie, Mario Gaudino and Ahmed Abouarab and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ihab Eldessouki

22 papers receiving 336 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ihab Eldessouki United States 9 159 129 72 71 61 23 337
Dennis John Kuo United States 10 79 0.5× 105 0.8× 30 0.4× 18 0.3× 77 1.3× 51 381
Monika Pogorzała Poland 12 53 0.3× 138 1.1× 48 0.7× 48 0.7× 82 1.3× 32 341
Grażyna Sobol Poland 13 66 0.4× 91 0.7× 40 0.6× 39 0.5× 70 1.1× 42 377
Joanne Derdak United States 12 84 0.5× 124 1.0× 79 1.1× 22 0.3× 48 0.8× 21 416
Rüdiger Liersch Germany 7 94 0.6× 109 0.8× 66 0.9× 24 0.3× 30 0.5× 20 320
Eileen Gillan United States 11 60 0.4× 56 0.4× 16 0.2× 156 2.2× 61 1.0× 22 374
Hallie Zietz United States 10 158 1.0× 53 0.4× 40 0.6× 66 0.9× 36 0.6× 12 353
Gail T. McDonald Canada 8 40 0.3× 43 0.3× 37 0.5× 30 0.4× 51 0.8× 17 317
Ana Garrido Spain 12 98 0.6× 33 0.3× 52 0.7× 25 0.4× 73 1.2× 26 324
Melissa M. Hudson United States 11 94 0.6× 61 0.5× 24 0.3× 28 0.4× 37 0.6× 20 429

Countries citing papers authored by Ihab Eldessouki

Since Specialization
Citations

This map shows the geographic impact of Ihab Eldessouki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ihab Eldessouki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ihab Eldessouki more than expected).

Fields of papers citing papers by Ihab Eldessouki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ihab Eldessouki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ihab Eldessouki. The network helps show where Ihab Eldessouki may publish in the future.

Co-authorship network of co-authors of Ihab Eldessouki

This figure shows the co-authorship network connecting the top 25 collaborators of Ihab Eldessouki. A scholar is included among the top collaborators of Ihab Eldessouki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ihab Eldessouki. Ihab Eldessouki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Shoukier, Mahran, et al.. (2021). Bosutinib in combination with pemetrexed in patients with selected metastatic solid tumors: A phase I study (NCT03023319).. Journal of Clinical Oncology. 39(15_suppl). 3022–3022. 2 indexed citations
3.
Rahouma, Mohamed, Adham Elmously, Magdy M. El‐Sayed Ahmed, et al.. (2020). Cardiac tumors prevalence and mortality: A systematic review and meta-analysis. International Journal of Surgery. 76. 178–189. 66 indexed citations
4.
Karim, Nagla Abdel, et al.. (2020). Stenting in Non-Small Cell Lung Cancer: How Does It Affect the Outcomes?. Asian Pacific Journal of Cancer Prevention. 21(1). 175–178. 1 indexed citations
5.
Ullah, Asad, et al.. (2020). Effect of personalized approach to therapy in non-small cell lung cancer (NSCLC) with liver metastasis with immunotherapy on outcomes.. Journal of Clinical Oncology. 38(15_suppl). e21504–e21504.
6.
Karivedu, Vidhya, et al.. (2019). Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience. SHILAP Revista de lepidopterología. 2019. 1–8. 13 indexed citations
7.
Karim, Nagla Abdel, et al.. (2019). Myeloid Sarcoma. Oncology Research and Treatment. 42(4). 219–224. 53 indexed citations
8.
Eldessouki, Ihab, et al.. (2019). Retrospective Study of the Effect of Statins on the Outcome of Lung Cancer Patients, University of Cincinnati Experience. Asian Pacific Journal of Cancer Prevention. 20(8). 2391–2396. 1 indexed citations
9.
Rahouma, Mohamed, Massimo Baudo, Mohamed Kamel, et al.. (2019). Pneumonitis as a complication of immune system targeting drugs?—a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. Journal of Thoracic Disease. 11(2). 521–534. 12 indexed citations
10.
11.
Ahmad, Imran, Ihab Eldessouki, C. Patrick, et al.. (2019). Correlation between K-RAS mutant subsets, TP53 mutation, and PD-L1 status in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 37(15_suppl). e14272–e14272. 1 indexed citations
12.
Eldessouki, Ihab, Mohamed Rahouma, Mohamed Kamel, et al.. (2019). Impact of tricyclic antidepressants, selective serotonin reuptake inhibitors, and other antidepressants on overall survival of patients with advanced lung cancer from 2004 to 2014: University of Cincinnati experience. Journal of International Medical Research. 47(12). 6016–6026. 8 indexed citations
13.
Ahmad, Imran, et al.. (2019). Phase I trial of chloroquine (CQ)/hydroxychloroquine (HCQ) in combination with carboplatin-gemcitabine (CG) in patients with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 3027–3027. 8 indexed citations
14.
15.
Karim, Nagla Abdel, et al.. (2018). GNQ-209P Mutation in Metastatic Uveal Melanoma and Treatment Outcome. Case Reports in Oncological Medicine. 2018. 1–5. 7 indexed citations
16.
Rahouma, Mohamed, Mohamed Kamel, Ahmed Abouarab, et al.. (2018). Lung cancer patients have the highest malignancy-associated suicide rate in USA: a population-based analysis. ecancermedicalscience. 12. 859–859. 44 indexed citations
17.
18.
Karim, Nagla Abdel, et al.. (2017). A Case Study in Advanced Lung Cancer Patients with Vimentin Over Expression. Clinical Laboratory. 63(10/2017). 1575–1579. 14 indexed citations
19.
Karim, Nagla Abdel, James Schuster, Ihab Eldessouki, et al.. (2017). Pulmonary sarcomatoid carcinoma: University of Cincinnati experience. Oncotarget. 9(3). 4102–4108. 43 indexed citations
20.
Karim, Nagla Abdel, et al.. (2017). PS06.06 Immune Checkpoint Markers in Lung Large Cell Neuroendocrine Carcinomas (L- LCNEC). Journal of Thoracic Oncology. 12(11). S1583–S1584. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dennis John Kuo Breakdown of academic impact, for papers by Monika Pogorzała Breakdown of academic impact, for papers by Grażyna Sobol Breakdown of academic impact, for papers by Joanne Derdak Breakdown of academic impact, for papers by Rüdiger Liersch Breakdown of academic impact, for papers by Eileen Gillan Breakdown of academic impact, for papers by Hallie Zietz Breakdown of academic impact, for papers by Gail T. McDonald Breakdown of academic impact, for papers by Ana Garrido Breakdown of academic impact, for papers by Melissa M. Hudson
Rankless by CCL
2026